新的,床边,组织因子依赖的凝血测定允许更好地评估组合抗血栓和抗血小板治疗
M B Holmes1, D J Schneider, M G Hayes
1Department of Medicine, University of Vermont College of Medicine, Burlington, USA.
Circulation
|October 25, 2000
概括
一种使用全血中的组织因子的新分析方法改善了对抗血小板和抗血小板药物组合的评估. 这种敏感的方法有助于优化药物剂量和监测治疗疗效.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
背景情况:
- 结合抗血小板和抗血栓药物的最佳使用需要敏感的疗效评估方法.
- 目前的方法可能缺乏精确治疗评估所需的灵敏度.
- 开发了一种新的测定方法,以提高评估药物疗效的灵敏度.
研究的目的:
- 开发和验证一种敏感的全血检测方法,用于评估抗血小板和抗血小板药物组合.
- 评估测试检测药物效应和添加物相互作用的能力.
- 为改善药物剂量选择和监测提供一个工具.
主要方法:
- 开发了一种基于微小变化的全血中组织因子启动的凝血的敏感试验.
- 使用玉米素抑制剂抑制了凝血的接触途径.
- 使用Hemochron ACT仪器测量凝血时间.
- 血液样本暴露于体外抗血栓和抗血小板药物的药理度.
主要成果:
- 该试验在健康志愿者中显示出可重复性 (平均凝血时间:125±17秒).
- 肝素,希鲁丁和埃诺沙巴林显著延长了凝血时间 (P<0.05).
- 检测到abciximab的附加效应与肝素和希鲁丁,但不是enoxaparin.
结论:
- 开发的测定有助于改善组合抗血栓和抗血小板疗法的剂量选择和定位.
- 这种方法有助于精确监测治疗方案.
- 该测试增强了个性化抗血小板和抗血栓药物使用的能力.
更多相关视频
08:50Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
Published on: January 9, 2026
392
08:01The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
Published on: February 27, 2026
174
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Clot Retraction and Fibrinolysis
6.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.0K
Venous Thrombosis III: Interprofessional Care
482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
